Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver
07 März 2008 - 3:15PM
PR Newswire (US)
DENVER, March 7 /PRNewswire-FirstCall/ -- Corgenix Medical
Corporation (OTC:CONX) (BULLETIN BOARD: CONX) , a worldwide
developer and marketer of diagnostic test kits, will be exhibiting
its AspirinWorks(R) Test at the American College of Family
Physicians 45th Annual Convention & Exhibition. ACOFP 2008
conference is being held March 12-14 at the Colorado Convention
Center in Denver. Corgenix representatives will be on-hand at booth
#807 during ACOFP to answer questions about the AspirinWorks test,
including its availability, the latest supporting clinical data and
ordering information. AspirinWorks is a simple urine test that
determines the effect of aspirin on platelets by measuring the
level of thromboxane production (aspirin's target). The higher the
levels of thromboxane, the stickier the blood platelets, and the
less impact the aspirin is having. This crucial information allows
physicians to individualize a patient's therapy. Unlike other
platelet tests, which require freshly drawn blood that must be
evaluated within four hours, the AspirinWorks test only requires a
urine sample that can be obtained in any doctor's office or patient
service center, making the test easy for both physician and
patient. "The ACOFP conference represents a special opportunity to
reach this medical specialty," said Corgenix' Clinical Affairs
Director Gordon Ens. "With their awareness of the differences among
individual patients, we're confident attendees will appreciate the
ability to identify individual response to aspirin." The
AspirinWorks Test, which was launched in the United States in June
2007 following FDA 510(k) clearance, is now available nationwide
through major medical reference laboratories, as well as direct to
consumers through HealthCheckUSA (http://www.healthcheckusa.com/).
The AspirinWorks Test Kit is an enzyme-linked immunoassay (ELISA)
to determine levels of 11 Dehydro Thromboxane B2 (11dhTxB2) in
human urine, which aids in the qualitative detection of aspirin
effect in apparently healthy individuals post ingestion. The test
targets a potential U.S. market of over 60 million individuals and
a potential global market exceeding 200 million individuals who
take aspirin regularly. Physicians and laboratories interested in
ordering the test can call 1-800-729-5661 x180, or e-mail: . More
information is also available at http://www.aspirinworks.com/. It
is important that individuals taking aspirin to lower the risk of a
heart attack or stroke consult a physician to determine what dose,
frequency and type of aspirin is appropriate for them to achieve
the most benefit with the fewest side effects. About Corgenix
Medical Corporation Corgenix is a leader in the development and
manufacturing of specialized diagnostic kits for immunology
disorders, vascular diseases and bone and joint disorders. Corgenix
diagnostic products are commercialized for use in clinical
laboratories throughout the world. The company currently sells over
50 diagnostic products through a global distribution network. More
information is available at http://www.corgenix.com/. Statements in
this press release that are not strictly historical facts are
"forward-looking" statements (identified by the words "believe",
"estimate", "project", "expect" or similar expressions) within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements inherently involve risks and uncertainties that
could cause actual results to differ materially from the
forward-looking statements. Factors that would cause or contribute
to such differences include, but are not limited to, continued
acceptance of the Company's products and services in the
marketplace, competitive factors, changes in the regulatory
environment, and other risks detailed in the Company's periodic
report filings with the Securities and Exchange Commission. The
statements in this press release are made as of today, based upon
information currently known to management, and the Company does not
undertake any obligation to publicly update or revise any
forward-looking statements. DATASOURCE: Corgenix Medical
Corporation CONTACT: William Critchfield, Senior VP and CFO of
Corgenix Medical Corp., +1-303-453-8903, ; or Media, Dan Snyders,
Vice President, Public Relations Supervisor of Armada Medical
Marketing, +1-303-623-1190, ext. 230, Fax, +1-303-623-1191, , for
Corgenix Medical Corporation Web site: http://www.corgenix.com/
http://www.aspirinworks.com/ http://www.healthcheckusa.com/
Copyright